Public-domain · open source
OpenJurist

197 F.2d 206

Docket No. 11125.

Merck & Co. v. Marzall

District of Columbia Circuit Court of Appeals

Argued Mareb 27, 1952.

Decided May 29, 1952.

District of Columbia Circuit Court of Appeals · decided 1952-05-29

2 counsel of record

Key passage — most relied on by later courts

““We are dealing solely with an application for a patent on the compound itself. Such an application must be denied if there has been any prior disclosure of the compound, even though no practical means for its isolation or manufacture was previously known.” [Emphasis ours.]”

quoted by 2 later decisions, including In re LeGrice, Application of Edward Burton Legrice

Applies 35 U.S.C. § 31

Relies on Eastman Kodak Co. v. Coe

Good law ✅— No negative treatment on recordhow we know

Decided 1952-05-29

How this case has been cited

Cited by 16 later decisions — most recently April 1970

1 federal appellate · 1 district ·

90195219601970decided

Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.

View the full empirical analysis of this case →

¶1Richard K. Stevens, Washington, D. C., with whom Robert E. Watkins and Ells-*207worth H. Mosher, Washington, D. C., were on the brief, for appellants.

¶2Clarence W. Moore, United States Patent Office, Washington, D. C., with whom E. L. Reynolds, Solicitor, United States Patent Office, Washington, D. C., was on the brief, for appellee.

¶3Before CLARK, WILBUR K. MILLER and WASHINGTON, Circuit Judges.

¶4WASHINGTON, Circuit Judge.

¶5This is a patent case under R.S. § 4915, 35 U.S.C.A. § 63. The application to the Patent Office sought to patent a chemical compound known as thiamin mononitrate, represented by the empirical formula C12 H17O4NBS. The Patent Office considered that this compound was disclosed by the prior patent to Williams, et al., No. 2,328,-594, issued September 7, 1943. After a trial the District Court made similar findings and dismissed the complaint.

¶6The testimony indicates that plaintiffs-appellants have made a substantial contribution to the art by isolating the mononitrate of thiamin and putting it into commercial production. However, this is not an application for a process patent. We are dealing solely with an application for a patent on the compound itself. Such an application must be denied if there has been any prior disclosure of the compound, even though no practical means for its isolation or manufacture was previously known. R.S. § 4886, 35 U.S.C.A. § 31; Eastman Kodak Co. v. Coe, 78 U.S.App.D.C. 403, 135 F.2d 836.

¶7The patent to Williams by its terms “relates to methods by which vitamin Bi [thiamin] and kindred compounds may be synthesized. … An object of the invention is to provide synthetic vitamin Bi, its salts and related compounds having the essential physiological properties thereof.” Application, p. 1, column 1. While the patent to Williams is for a process, not a compound, its disclosures are important as showing what compounds were known to the art at the time of the present application. Claims 9 and 10 of the Williams patent describe antineuritic compounds having stated structural formulae; both parties agree that these compounds may properly be termed the monoacetate of thiamin (Claim 9) and the monobromide of thiamin (Claim 10) . To this extent Williams admittedly discloses the existence of monosalts of thiamin.

¶8As to Claim 8 of the Williams patent, there is controversy. That claim is as follows:

¶9“8. The process of producing anti-neuritic compounds which comprises reacting an ester of the group having the formulae

¶10

¶11in which X and X1 are selected from the group consisting of the halide, acetate, lactate, benzoate, nitrate, phosphate and sulphate radicles, with 4-methyl-5-/J -hydroxy-ethyl thiazole.”

¶12From the text of the Williams patent it appears that the chemical structures illustrated above are pyrimethyl groups, and that the crux of Williams’ invention is the coupling of such a pyrimethyl group with a thiazole group. It will be further noted that Claim 8 requires certain additions to be made to the pyrimethyl group, as indicated by the symbols X and X1. A nitrate radicle is specifically .contemplated as a possible member of the class represented by these symbols. Clearly, then, Claim 8 discloses the possibility of a nitrate compound of thiamin. True, that claim does not specifically refer to mono-salts ; but neither does it refer to di-salts or any other restricted category. In terms it contemplates a variety of thiamin com*208pounds which will contain “the halide, acetate, lactate, benzoate, nitrate, phosphate and sulphate radicles.” In fact, Williams says that the acid radicle "may be varied almost at will.” Williams’ application, p. 7, column 2, lines 42-57. The nitrate radicle is, of course, an acid radicle.

¶13Comparison of chemical structures also reveals the extent of the disclosures made by Williams. The structure of thiamin mononitrate, as set forth by plaintiffs-appellants, is the homologue of that of thiamin monobromide, as set forth by Williams.1 Both structures represent the coupling of moieties revealed by Williams.2

¶14We think the Patent Office and the District Court correctly viewed the Williams disclosures as including the mononi-trate of thiamin, the substance which plaintiffs-appellants seek to patent. The judgment of the District Court will accordingly be

¶15Affirmed.

/197/f2d/206 · .json · Public domain